Sales & Marketing News | pharmaphorum

News

Vounatsos heading for exit as Biogen sidelines Aduhelm

Biogen has announced a major revamp of its business that will see chief executive Michel Vounatsos depart the company, and all commercial activities related to troubled Alzheimer's therapy

News

Idorsia is first to EU market with orexin insomnia drug

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and

News

AstraZeneca plans new US R&D hub as revenues rocket

AstraZeneca has revealed plans to set up a new strategic R&D hub in Cambridge, Massachusetts as it reported a massive increase in first-quarter revenues, driven by COVID-19 and oncology

News

Pfizer/Biohaven migraine drug rimegepant gets EU green light

Pfizer's $1.2 billion licensing deal with Biohaven for rights to oral migraine drug rimegepant is approaching a payoff after the European Commission approved the drug.

News

Merck makes $3.2bn from COVID-19 drug Lagevrio in Q1

Orders for Merck & Co's oral antiviral for COVID-19 helped to swell the drugmaker's first quarter revenues by a massive 50%, although underlying growth was also strong.

News